Influenza

Sanofi Pasteur has received approval from US Food and Drug Administration (FDA) for its Fluzone Intradermal Quadrivalent vaccine.

The vaccine will provide protection against four strains of influenza virus.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The FDA approved the vaccine’s supplemental biologics license application (sBLA) for adults aged 18-64 for active immunisation to prevent influenza, caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Sanofi Pasteur US scientific and medical affairs vice-president David Greenberg said: "Influenza B is a common cause of influenza-related morbidity and mortality across all age groups.

"Fluzone Intradermal Quadrivalent vaccine will offer another influenza vaccination option for health care providers and their adult patients with broad coverage against influenza viruses that may be predominant, coupled with the efficiency of using the intradermal microinjection system."

See Also:

"According to the company, the study showed the vaccine can improve vaccine effectiveness by generating immune responses to influenza strains from both B lineages simultaneously."

Approval for the vaccine was based on results from a Phase III clinical trial, which comprised 3,355 adults.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial included B strains from both lineages, to two trivalent intradermal controls and licensed trivalent Fluzone Intradermal vaccine containing a B strain of one lineage and an investigational intradermal vaccine that contained a B strain from the opposite lineage.

According to the company, the study showed the vaccine can improve vaccine effectiveness by generating immune responses to influenza strains from both B lineages simultaneously.

Sanofi Pasteur plans to introduce the vaccine in the US during 2015-2016 influenza season. Fluzone Intradermal vaccine was previously available in trivalent formulation for three years.

Image: Image of newly identified H1N1 influenza virus, taken in Centers for Disease Control and Prevention (CDC) Influenza. Photo: courtesy of Svajcr.